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RAMPs (receptor activity modifying proteins) impart
remarkable effects on G protein-coupled receptor (GPCR) sig-
naling. First identified through an interaction with the calcito-
nin receptor-like receptor (CLR), these single transmembrane
proteins are now known to modulate the in vitro ligand binding
affinity, trafficking, and second messenger pathways of numer-
ous GPCRs. Consequently, the receptor-RAMP interface repre-
sents an attractive pharmacological target for the treatment of
disease. Although the three knownmammalianRAMPs differ in
their sequences and tissue expression, results from in vitro bio-
chemical and pharmacological studies suggest that they have
overlapping effects on the GPCRs with which they interact.
Therefore, to determine whether RAMP2 and RAMP3 have
distinct functions in vivo, we generated mice with targeted
deletions of either the RAMP2 or RAMP3 gene. Strikingly, we
found that, although RAMP2 is required for survival, mice
that lack RAMP3 appear normal until old age, at which point
they have decreased weight. In addition, mice with reduced
expression of RAMP2 (but not RAMP3) display remarkable
subfertility. Thus, each gene has functions in vivo that cannot
be accomplished by the other. Because RAMP2, RAMP3, and
CLR transduce the signaling of the two potent vasodilators
adrenomedullin and calcitonin gene-related peptide, we
tested the effects of our genetic modifications on blood pres-
sure, and no effects were detected. Nevertheless, our studies
reveal that RAMP2 and RAMP3 have distinct physiological
functions throughout embryogenesis, adulthood, and old age,
and themice we have generated provide novel genetic tools to
further explore the utility of the receptor-RAMP interface as
a pharmacological target.
The identification of receptor activity modifying proteins
(RAMPs)2 1–3 has revolutionized our current understanding of
the mechanism through which class II G protein-coupled
receptors (GPCRs) bind to their peptide ligands. First identified
in association with the calcitonin receptor-like receptor (CLR;
formerly called CRLR), either of these three single pass trans-
membrane proteins can bind to a GPCR, chaperone it to the
plasma membrane, and alter the ligand binding affinity of the
receptor (1). For example, a CLRRAMP1 complex preferen-
tially and specifically binds to calcitonin gene-related pep-
tide (CGRP), whereas a CLRRAMP2 or CLRRAMP3 com-
plex will preferentially bind to adrenomedullin (AM),
another peptide vasodilator. Thus, the different spatial and
temporal expression patterns of RAMP1, RAMP2, and RAMP3
determine how a cell or tissue will sense and respond to either
extracellular CGRP or AM.
Biochemical studies using heterologous overexpression of
RAMPs in cultured cells have demonstrated that this general
mechanism also applies to several other GPCRs of the class II
family, including calcitonin receptor, parathyroid receptors 1
and 2, vasointestinal peptide/pituitary adenylate cyclase-acti-
vating peptide 1 (VIP/VPAC1) receptor, and glucagon receptor
(2, 3).More recently, Bouschet et al. (4) have also demonstrated
that RAMP1 or RAMP3 can functionally target a class III recep-
tor, the calcium sensing receptor, to the plasma membrane.
Therefore, it is likely that RAMP proteins have evolved to
impart a highly controllable mechanism for modulating GPCR
signaling thatmay be broadly applicable tomanyGPCRs (5). As
a consequence, the pharmacological and biochemical study of
the RAMP-receptor interaction has been geared toward
identifying compounds that exploit this interface as a poten-
tial drug target for the specific modulation of GPCR signaling
for the treatment of human disease (6). One such compound,
BIBN4096BS, which is currently in clinical trials for the treat-
ment of migraine, acts as a selective CGRP antagonist by inter-
feringwith the hCLRhRAMP1 interaction (7, 8). Yet, the devel-
opmental and physiological consequences of genetically
altering RAMP function or expression in thewhole animal have
not been addressed experimentally.
Receptor-associated RAMPs have been linked with receptor
glycosylation, receptor trafficking, ligand binding, and alter-
ation of secondmessenger signaling (recently reviewed in Refs.
9 and 10). However, these ascribed cellular functions are not
consistently conserved among the different receptorRAMP
complexes and are highly affected by the choice of cell type and
species of RAMPs studied (9). Moreover, pharmacological
studies with the most well characterized receptorRAMP
pairs, CLRRAMP1–3 and calcitoninRAMP1–3, demon-
strate varying degrees of overlap in the absolute ligand binding
affinity imparted by the different RAMPs. For example,
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CLRRAMP1–3 complexes can all bind AM or CGRP but with
different affinities (11–13), and calcitoninRAMP1–3 com-
plexes can form amylin receptors with highly variable affinities
(3, 14) or CGRP receptors (15, 16), depending on the cell type
studied. Thus, it remains unclear to what degree the three
mammalian RAMPs have overlapping functions or whether
they can functionally compensate for each other in vivo. To
address these questions, we used gene targeting to generate
mice with targeted deletions of either the RAMP2 or RAMP3
genes and have determined the effects of their complete
absence (in homozygous null mice) and of their reduced
expression (in heterozygous mice).
EXPERIMENTAL PROCEDURES
Generation of Mice with Targeted Deletion of the RAMP2 or
RAMP3Gene—Togenerate the targeting vectors, a 129S6/SvEv
genomic library was screened for phage clones containing the
5 portions of the RAMP2 and RAMP3 genes using DNA frag-
ments isolated from hRAMP2 or hRAMP3 expression plasmids
(kindly provided byDr. Steven Foord,GlaxoSmithKline). Using
convenient restriction sites within the genomic clones, 5 and
3 regions of homology were subcloned into the multiple clon-
ing site of a gene-targeting vector that contained a phospho-
glycerate kinase-neomycin cassette and an a herpes simplex
virus-thymidine kinase cassette. The final targeting vectors
were linearized with NotI before electroporation into embry-
onic stem cells.
Standard gene targeting methods were utilized to generate
embryonic stem cells and mice with a targeted deletion of the
RAMP2 gene or a targeted deletion of the RAMP3 gene (17).
Briefly, 129S6/SvEv-TC-1 embryonic stem cells were electro-
porated with the linearized targeting vectors shown in Figs. 1A
and 2A, respectively. After applying positive (G418) and nega-
tive (gancyclovir) selection, positive embryonic stem cell clones
were identified by Southern blot and/or PCR. The frequency of
homologous recombination in the survivingG418/gancyclovir-
resistant colonies was 5% for RAMP2 and 1.5% for RAMP3.
Male chimeric mice that transmitted the targeted allele were
bred to 129S6/SvEv females to establish isogenic lines.
For PCR-based genotyping of the RAMP2-targeted locus, we
used the following three primers: primer 1, 5-CTGAACT-
GAACAGCAGGGCCA-3; primer 2, 5 CGGCTACTTC-
CCACTTAATGCTG-3; and primer 3, 5GCTTCCTCTTG-
CAAAACCACA-3. Primers 1 and 3 amplify a 1.2-kb-targeted
band, whereas primers 1 and 2 amplify a 1.6-kb wild type band.
For PCR-based genotyping of the RAMP3-targeted locus, we
used the following four primers: primer 1, 5-GCCCATGAT-
GTTGGTCTCCA-3; primer 2, 5 GGTCATTAGGAGC-
CACGTGT-3; primer 3, 5GCTTCCTCTTGCAAAAC-
CACA-3; and primer 4, 5GGGCTAAAGAAGCCACAGCT-
3. Primers 1 and 3 amplify a 2.0-kb-targeted band, whereas
primers 2 and 4 amplify a 1.4-kb wild type band.
Gene Expression Analysis—RAMP2, RAMP3, and calcrl gene
expression was analyzed by quantitative reverse transcription
(RT)-PCRwith theMx3000PQ-PCRmachine fromStratagene.
Primers for RAMP2 amplification were 5-CAGAATCAATC-
TCATCCCACTGAC-3 and 5-GTCCATGCAACTCTTGT-
ACTCATACC-3. The probe sequence for RAMP2 detection
was 5-FAM-ATGGAAGACTACGAAACACATGTCCTAC-
CTTG-TAMRA-3. Primers for RAMP3 amplification were 5-
GGTCATTAGGAGCCACGTGT-3 and 5-GGGCTAAAC-
AAGCCACAGCT-3. The probe sequence for RAMP3
detection was 5-FAM-CACGATTCTGTGTCCAGTGTGG-
GCTG-TAMRA-3. Primer and probe sequences for detection
of calcrl gene expression were previously described (18). -Ac-
tin served as an internal control for all reactions. The primers
used for -actin amplification were 5-CTGCCTGACGGC-
CAAGTC-3 and 5-CAAGAAGGAAGGCTGGAAAAGA-3.
The probe sequence for -actin detection was 5-TET-CAC-
TATTGGCAACGAGCGGTTCCG-TAMRA-3. RNA was
isolated from adult tissues or embryonic day 13.5 embryos with
TRIzol reagent (Invitrogen) and subsequently DNase treated
and purified with an RNeasy Mini kit (Qiagen). 200 ng of total
RNA was used in each reaction. The Ct method (19) was
used to determine the relative levels of gene expression and
shown as a percentage of wild type. All assays were repeated
three times, each with duplicates.
Measurement of Basal Blood Pressure, Heart Rate, and Urine
Chemistry—Blood pressures and heart rates were measured on
unanesthetized mice by a computerized tail cuff system (20).
Urine and protein creatinine were measured at the University
of North Carolina-Chapel Hill Animal Clinical Chemistry Core
Facility.
Experimental Animals—Unless otherwise noted, experi-
mental animals were 4–8 months old and maintained on an
isogenic 129S6/SvEv-TC-1 background. Control animals for all
experiments consisted of wild type age- and gender-matched
littermates. All experiments were approved by the Institutional
Animal Care and Use Committee of The University of North
Carolina-Chapel Hill.
Statistics—Statistical analyses formultiple comparisonswere
performed with one way analysis of variance by JMP Software,
SAS Institute. Error bars represent S.E. of the means. Differ-
ences were considered significant with a p value of 0.05.
RESULTS
Generation of HeterozygousMice with Targeted Disruption of
the RAMP2 Gene—Mice in which exons 1 and 2 of the RAMP2
gene were deleted by homologous recombination were gener-
ated using the targeting strategy shown in Fig. 1A. The dis-
rupted allele, which lacks the RAMP2 promoter, 5-untrans-
lated region translation start site, and exons 1 and 2, was
confirmed by genomic PCR (Fig. 1B). To confirm that the gene
targeting effectively disrupted transcription of the RAMP2
gene, quantitative reverse transcription-PCR for RAMP2 RNA
was performed on total RNA isolated from whole embryos. As
expected and shown in Fig. 1C, RAMP2/ embryos expressed
approximately half the wild type RAMP2 RNA levels (58%,
p  0.001 versus wild type), whereas RAMP2/ embryos had
no detectable levels of RAMP2 RNA, thus confirming correct
gene targeting of the RAMP2 gene (Fig. 1C). To determine
whether genetic reduction of RAMP2 caused a homeostatic
compensation in the expression of the RAMP3 or calcrl genes,
we measured the expression of these genes in the heart and
kidneys of adult RAMP2/ animals and in total RNA isolated
frommid-gestation RAMP2/ embryos. As shown in Fig. 1D,
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we found no significant compensatory increase in the expres-
sion of either RAMP3 or calcrl in RAMP2/ or RAMP2/
mice compared with wild type controls, demonstrating that the
genetic reduction of RAMP2 does not result in a compensatory
up-regulation of RAMP3 or calcrl gene expression.
Generation of Mice Lacking the RAMP3 Gene—Homozygous
null mice for the RAMP3 gene were generated by homologous
recombination using the targeting strategy shown in Fig. 2A. The
disrupted allele, which lacks exons 2 and 3 of the RAMP3 gene
(coding for amino acids 19–147 of 147 total amino acids), was
detected by Southern blot analysis using a genomic probe frag-
ment located outside the areas of homology (Fig. 2B) and by
genomic PCR (Fig. 2C). The correctly targeted allele was further
confirmedbydirect sequencing (datanot shown).To confirm that
the gene targeting effectively disrupted transcription of full-length
RAMP3 mRNA, quantitative reverse transcription-PCR for
RAMP3mRNA was performed on total RNA isolated from adult
kidneys. As expected, RAMP3/ mice expressed approximately
half thewild typeRAMP3RNA levels (45%,p 0.0001 versuswild
type), whereas RAMP3/ mice had no detectable levels of
RAMP3 RNA, thus confirming the complete loss of RAMP3
expression in adult homozygous mice (Fig. 2D). To determine
whether genetic deletion of RAMP3 caused a homeostatic com-
pensation in the expression of the RAMP2 or calcrl genes in adult
animals, we measured the expression of these genes in the heart
and kidneys ofRAMP3/ animals. As shown inFig. 2E, we found
no significant compensatory increase in the expression of either
RAMP2 or calcrl genes in RAMP3/ mice compared with wild
type controls, demonstrating that the genetic deletion of RAMP3
does not impact on the regulation of RAMP2 or of calcrl gene
expression.
FIGURE 1. Gene targeting of RAMP2. A, schematic representation of the
strategy used to disrupt the RAMP2 gene in mice. The promoter region and
exons 1 and 2 of RAMP2, including the initiator methionine were deleted by
homologous recombination. B, BamHI X, Xho, Xb, and Xba and P1, P2, and P3
primers used for screening and genotyping. B, genomic PCR for detection of
the wild type and targeted alleles using total embryonic DNA extracts and the
primers depicted in Fig. 1A. C, quantitative RT-PCR for detection of RAMP2
mRNA transcripts using total embryonic RNA extracts and the primers and
probes described under “Experimental Procedures.” ND, not detected.
D, quantitative RT-PCR for detection of RAMP2, RAMP3, and calcrl mRNA tran-
scripts using total RNA extracted from the hearts and lungs of RAMP2/
adult mice and RAMP2/ embryos.
FIGURE 2. Gene targeting of RAMP3. A, schematic representation of the
strategy used to disrupt the RAMP3 gene in mice. Exons 2 and 3 of RAMP3,
including the last 129 amino acids (of 147 total), the stop codon, and the
3-untranslated region were deleted by homologous recombination. Shown
are AvrII (A), Kpn (K), PvuII (P), and SacI (S) and P1, P2, P3, and P4 primers used
for screening and genotyping. B, Southern blot for detection of the wild type
and targeted alleles using genomic DNA and the probe fragment depicted in
Fig. 2A. C, genomic PCR for detection of the wild type and targeted alleles
using total DNA extracts and the primers depicted in Fig. 2A. D, quantitative
RT-PCR for detection of RAMP3 mRNA transcripts using total RNA extracted
from adult kidneys and the primers and probes described under “Experimen-
tal Procedures.” ND, not detected. E, quantitative RT-PCR for detection of
RAMP2 and calcrl mRNA transcripts using total RNA extracted from the hearts
and lungs of RAMP3/ adult mice.
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RAMP2 Is Essential for Survival and Normal Fertility—In
marked contrast, although the loss of RAMP3 did not affect the
survival of RAMP3/ mice to adulthood, we found that
genetic loss of RAMP2 caused embryonic lethality, as no
RAMP2/ pups were born alive to heterozygotematings. This
remarkable contrast in phenotypes (embryonic lethality of
RAMP2/ mice versus survival of RAMP3/ mice) demon-
strates that these two genes have significantly different func-
tions during embryonic development.
Offspring from RAMP3/ matings were born in the
expectedMendelian ratio of 1:2:1 (26 RAMP3/:48 RAMP3/:
25 RAMP3/ pups from 15 litters) and had litter sizes compa-
rable with isogenic control matings (6.6 pups/litter for
RAMP3/ matings versus 6.0 pups/litter for 129S6/SvEv iso-
genic controlmatings) (Fig. 3). In contrast, although the ratio of
wild type:heterozygote genotypes for viable pups born to
RAMP2/ matings was in the expected Mendelian distribu-
tion of 1:2 (22 RAMP2/:44 RAMP2/ pups from 29 litters),
the average litter size was significantly reduced to 2.1 pups/
litter at weaning. This markedly reduced litter size was signifi-
cantly below the expected litter size of 4.5 pups/litter, which
took into consideration the gestational loss of RAMP2/ null
embryos (further confirmed by the assessment of litter sizes for
calcrl heterozygote matings in which there was gestational loss
of null embryos (Fig. 3) (18). Thus, although genetic loss of
RAMP3 was dispensable for normal fertility, a modest genetic
reduction of RAMP2 was sufficient to cause marked subfertil-
ity, demonstrating that the two genes maintain distinct physi-
ological functions during adulthood.
Aged RAMP3/ Mice Fail to Gain Weight—RAMP3/
mice survived to adulthood, reproduced, and displayed no
obvious phenotypic defects until 6 months of age.
Although the body weights of young RAMP3/ mice did
not differ from their wild type controls up to 6 months of
age (Table 1), we noticed that older RAMP3/ mice (9–10
months of age) weighed nearly 9 grams less than age-
matched wild type mice (wild type mice weighed 36.1  1.9 g
versus 27.3  1.1 g for age-matched RAMP3/ mice) (Fig.
4B). In contrast, aged RAMP2/ mice did not differ signif-
icantly in body weight from their wild type littermates (wild
type weighed 28.3  0.5 g versus 28.8  0.7 g for age-
matched RAMP2/ mice) (Fig. 4A). Despite their visibly
lean appearance, we found no significant differences in food
or water intake in either young or aged RAMP3/ mice
compared with their age-matched wild type controls (Table
1). Moreover, RAMP3/ mice, similar to their wild type
counterparts, survived to at least 18 months of age with no
obvious decline in health. Because RAMP3 is highly
expressed in the proximal tubule of the kidney, we also com-
pared urine volume and kidney function (as determined by
protein:creatinine ratio) between RAMP3/ mice and wild
type controls and found no obvious differences (Table 1).
The body weights, feeding behavior, and kidney function of
RAMP2/ mice or calcrl/ mice did not differ from wild
type control littermates (Table 1).
Blood Pressure andHeart Rates AreUnaffected in RAMP2/
and RAMP3/ Mice—Because CLR is the best characterized
receptor partner for RAMP2 and RAMP3 and because CLR
binds to two potent peptide vasodilators (AM and CGRP),
we sought to compare the blood pressure and heart rates of
RAMP2/ and RAMP3/ mice to those of calcrl/ (18)
and wild type mice using a computerized tail cuff system. As
shown in Table 1, we found that reduction of RAMP2 to
50% of wild type levels and the complete absence of
RAMP3 had no effect on the basal blood pressure of con-
scious animals compared with wild type mice or with
FIGURE 3. Severely reduced fertility in RAMP2/ mice. Average litter sizes
at weaning resulting from heterozygote matings of the genotype indicated.
The number at the bottom of each bar represents the total number of litters.
Litter size of calcrl/ matings is significantly reduced because of the previ-
ously reported embryonic lethality of calcrl/ embryos (18). *, p  0.05 by
analysis of variance.
TABLE 1
Phenotypic analysis of RAMP2/ and RAMP3/ mice
Wild type mice were age-, strain-, and gender-matched SvEv129/6.
Wild type RAMP2/ RAMP3/ calcrl/
Body weight (4–6 mo., g) 25.8  0.6 27.3  0.8 24.3  0.5 25.6  0.9
Food intake (24 hr, g) 4.6  0.2 4.2  0.2 4.1  0.2 4.5  0.3
Water intake (24 hr, ml) 3.6  0.2 3.7  0.2 3.4  0.1 3.4  0.2
Urine volume (24 hr, ml) 1.0  0.1 1.3  0.1 1.1  0.2 1.0  0.1
Urine protein/creatinine 0.12  0.02 0.12  0.01 0.08  0.01 0.10  0.03
Mean blood pressure (mm Hg) 106  5 105  3 106  5 111  5
Mean heart rate (beats/min) 641  18 635  9 605  10 591  17
Left ventricle/body weight ratio (3–6 months) 4.11  0.22 4.13  0.14 3.98  0.14 3.97  0.17
RAMP2 and RAMP3 Gene-targeted Mice
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calcrl/ mice. Moreover, we found no overt differences in
the heart rates among the genotypes tested (Table 1).
DISCUSSION
In summary, we used gene targeting to generate two inde-
pendent mouse lines with deletion of either the RAMP2 or
RAMP3 genes. Gene expression analysis in mice with reduced
or absent RAMP2 levels or a complete lack of RAMP3 did not
reveal any compensatory up-regulation of either RAMP3 or
RAMP2 gene expression, respectively, supporting our conclu-
sion that there is no functional redundancy at the transcrip-
tional level between RAMP2 and RAMP3 in vivo. We did
observe a general trend for significantly reduced expression of
RAMP2, RAMP3, and calcrl compared with wild type mice in
themodels we tested (Figs. 1D and 2E), which is likely reflective
of the high sensitivity of these genes to altered physiological
homeostasis (11, 12).
Although the biochemical and pharmacological profiles of
RAMP2 and RAMP3 appear to overlap for certain GPCRs
(CLR, calcitonin, andVIP/VPAC1), our genetic studies demon-
strate that the two genes have distinct roles throughout the life
of an animal. During embryonic development, RAMP2/
mice failed to survive, whereas RAMP3/ mice appeared nor-
mal up to 6 months of age. During adulthood, the loss of
RAMP3 had no apparent effect on fertility. In contrast, a mod-
est genetic reduction of RAMP2 in heterozygous mice was suf-
ficient to cause a marked reduction in litter size, which is sim-
ilar to the phenotype we have previously characterized formice
with a genetic reduction ofAM(21). Finally, in aged animals, we
found that RAMP3 (but not RAMP2) plays an important role in
maintaining normal body weight; however, the physiological
mechanisms that account for this phenotype have not yet been
resolved.
Our studies to address the regulation of blood pressure and
heart rate in these mice are consistent with our recent findings
demonstrating that genetic alteration of AM peptide levels
from 50–140%wild type levels does not affect basal blood pres-
sure. These results are also consistentwith another recent study
where transgenic overexpression ofmRAMP2 in smooth mus-
cle cells had no effect on basal or induced changes in blood
pressure (22). Lu et al. (23) have also shown that genetic dele-
tion of -CGRP does not alter basal blood pressure in mice.
Taken together, our results indicate that in vivo genetic alter-
ation of RAMP2, RAMP3, or calcrl expression (the receptor
signaling components required for transducing the signal of
two potent vasodilators, AM and CGRP) does not impact on
basal blood pressure regulation in mice. Thus, the use of
CLRRAMP2 or CLRRAMP3 as pharmacological targets for
the treatment of hypertension in humans should be carefully
evaluated.
Our most significant data stem from the direct comparison
of phenotypes for the RAMP2 and RAMP3 gene-targeted mice.
Although modest changes in the genetic dosage of the RAMP2
gene have profound effects on survival and reproduction, com-
plete absence of the RAMP3 gene seems to have little or no
effect on mice until old age. These in vivo findings are consist-
ent with the concept that RAMP2 acts to mediate the basal
effects of normal GPCR signaling, whereas RAMP3 may
become induced under physiological conditions (24) or disease
(25) to alter the signaling of GPCRs (10). This concept is further
supported by biochemical studies that demonstrate that
RAMP3 (but not RAMP2) contains an intracellular PDZ motif
capable of binding to N-ethylmaleimide-sensitive factor and
Na/H exchanger regulatory factor to change receptor inter-
nalization and trafficking (26, 27). Thus, the continued study of
these genetically engineered mouse models under normal con-
ditions and disease states, as well as cell lines derived from
them,will provide useful tools for unraveling the functional role
of RAMP2 andRAMP3 inmodulatingGPCR signaling and test-
ing their potential utility as pharmacological targets for the
treatment of human disease.
FIGURE 4. Reduced body weights in aged RAMP3/ mice (but not aged
RAMP2/ mice). A, body weights of 9 –10-month-old RAMP2/ mice com-
pared with their age-matched isogenic controls (Student’s t test, p  0.6,
n  7 for each group). B, body weights of 9 –10-month-old RAMP3/ mice
compared with their age-matched, isogenic controls (Student’s t test,
p  0.001, n  10 for each group).
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